J. Goldstein

发表

Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs

T. MacDonald, S. Morant, J. Goldstein, 2003, Gut.

Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib.

J. Schwartz, N. Maniadakis, J. Goldstein, 2000, Rheumatology.

Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib.

J. Goldstein, J. Goldstein, 2000, The Journal of rheumatology. Supplement.

Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR)

Á. Lanas, F. Chan, D. Peura, 2012, Alimentary pharmacology & therapeutics.

Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.

M. Kuss, R. Hubbard, J. Goldstein, 2001, Clinical therapeutics.

Reduced incidence of upper gastrointestinal ulcer complications with the COX‐2 selective inhibitor, valdecoxib

G. Eisen, W. Stenson, J. Goldstein, 2004, Alimentary pharmacology & therapeutics.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

R. Makuch, T. Pincus, L. Simon, 2000, JAMA.

THU0183 Significantly improved upper gastrointestinal (ugi) tolerability with celecoxib, a cox-2 specific inhibitor, compared with conventional nsaids. the success i trial

G. Eisen, W. Stenson, J. Goldstein, 2001 .

Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro‐oesophageal reflux disease – comparator study of esomeprazole, lansoprazole and pantoprazole

D. Morgan, J. Pandolfino, M. Illueca, 2010, Alimentary pharmacology & therapeutics.

Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy

G. Eisen, I. Gralnek, J. Aisenberg, 2007, Alimentary pharmacology & therapeutics.

Clinical trial: the incidence of NSAID‐associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric‐coated naproxen alone

M. Hochberg, C. Hwang, M. Sostek, 2010, Alimentary pharmacology & therapeutics.

OP0138 Relative gastrointestinal toxicity of cox-2 specific and traditional nsaids in a high-risk population from a health maintenance organisation

J. Schwartz, J. Goldstein, T. Burke, 2001 .

Does concomitant use of paracetamol potentiate the gastroduodenal mucosal injury associated with aspirin? A prospective, randomised, pilot study

J. Niebruegge, J. Berkes, J. Boike, 2012, Alimentary pharmacology & therapeutics.

Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac

J. Lefkowith, J. Goldstein, T. Burke, 2002, Alimentary pharmacology & therapeutics.

Adherence to proton pump inhibitors or H2‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs

J. Dieleman, M. Sturkenboom, T. Burke, 2003, Alimentary pharmacology & therapeutics.

Clinical trial: healing of NSAID‐associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazole

J. Johanson, J. Goldstein, C. J. Hawkey, 2007, Alimentary pharmacology & therapeutics.

Clinical trial: endoscopic evaluation of naproxen etemesil, a naproxen prodrug, vs. naproxen – a proof‐of‐concept, randomized, double‐blind, active‐comparator study

J. Škopek, J. Goldstein, K. Sewell, 2010, Alimentary pharmacology & therapeutics.

The impact of low‐dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non‐selective non‐steroidal anti‐inflammatory drug or a cyclo‐oxygenase‐2‐selective inhibitor

W. Dodge, J. Goldstein, H. Schwartz, 2006, Alimentary pharmacology & therapeutics.

Letter: mucosal injury with exposure to low‐dose nonsteroidals

J. Goldstein, B. G. Vancura, 2012, Alimentary pharmacology & therapeutics.

Intragastric acid control in non‐steroidal anti‐inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole

D. Silberg, P. Miner, J. Goldstein, 2006, Alimentary pharmacology & therapeutics.

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

R. Hubbard, P. Correa, J. Goldstein, 2001, American Journal of Gastroenterology.